Table 1 Patient clinical characteristics.
From: Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia
Variable | Count (%) | Variable | Count (%) |
|---|---|---|---|
Age (years) | HCT-comorbidity index | ||
<60 | 127 (49%) | 0 | 53 (21%) |
≥60 | 130 (51%) | 1,2 | 80 (31%) |
Sex | >2 | 124 (48%) | |
Female | 128 (50%) | Karnofsky Score | |
Male | 129 (50%) | <90 | 106 (41%) |
Conditioning Intensity | ≥90 | 147 (57%) | |
MAC | 127 (49%) | ATG Usage | |
RIC with melphalan | 62 (24%) | No | 202 (79%) |
RIC without melphalan | 46 (18%) | Yes | 55 (21%) |
NMA | 22 (9%) | Graft Type | |
Race | Bone Marrow | 39 (15%) | |
Caucasian | 217 (84%) | Cord Blood | 24 (9%) |
Other | 32 (12%) | Peripheral Blood | 194 (75%) |
Donor Group | ELN Risk Group | ||
Cord Blood | 18 (7%) | Favorable | 44 (17%) |
Haploidentical Related | 20 (8%) | Intermediate | 111 (43%) |
HLA-identical Sibling | 37 (14%) | Adverse | 102 (40%) |
Matched Unrelated | 155 (60%) | AML Group | |
Mismatched | 21 (8%) | De novo | 226 (88%) |
Multiple Donors | 6 (2%) | Therapy-Related | 10 (4%) |
Site-reported Flow Cytometry MRD | Transformed MDS/MPN | 21 (8%) | |
Negative | 222 (86%) | Baseline Mutation | |
Positive | 25 (10%) | NPM1 and/or FLT3-ITD | 106 (41%) |
